Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Barclays PLC (BCS) vs Becton Dickinson and Co (BDX) Price & Performance

Barclays PLCTrade
Becton Dickinson and CoTrade

Price performance (Past 24H)

Key statistics

Barclays PLC vs Becton Dickinson and Co — how do they compare? Barclays PLC trades at $27.87 (market cap $94.10B), while Becton Dickinson and Co trades at $181.29 (market cap $48.93B). The key difference: Barclays PLC is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.

BCSBDX
Market Cap
$94.10B$48.93B
Sector
FinancialsHealth
52-Week High
$28.56$185.39
52-Week Low
$19.36$138.62
Dividend Yield
2.18%2.34%
Enterprise Value
$65.03B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Barclays PLC

Barclays PLC (BCS) trades at $27.93, down 0.89% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.90 exceeding the $0.89 estimate. Revenue grew to $29.14 billion in 2025, with a net income margin of 25.51%. Analyst consensus is 68% buy, though recent news highlights a securities class action investigation.

The outlook for BCS is positive given earnings momentum and a low P/E of 10.73, but risks include the legal investigation and rising costs noted in Q2 2026. Investment opportunity lies in valuation discount and dividend yield, while sentiment is mixed due to near-term headwinds.

Becton Dickinson and Co

BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.

The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Barclays PLC

Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments

Read more on BCS

About Becton Dickinson and Co

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.

Read more on BDX